We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thank you T6.1. Just found the article myself too. (add HTML at the end - I removed it so the link won't get removed)
nytimes.com/2020/07/04/world/coronavirus-updates
I'm not worried. Just hoping the price going down a bit more so I can buy more. As far as I could see, LAGO was selling loads. Perhaps it suits some big players the price to be lower? Who knows? Or are they building up a bigger stock price increase for publicity? Sorry, this is total speculations and I'm not sure if such a thing would be allowed??
The Iranian study was a positive indication re: Interferons. Why initiate HIBISCUS study if no positive nudges of Interferon beta1a treatment being effective?
NY Times article says:
The Solidarity trial is also continuing its explorations of two other treatment strategies: one involving remdesivir, an antiviral that has been shown to speed recovery in patients hospitalized with Covid-19, and a second that combines lopinavir/ritonavir with interferon beta-1a, which decreases inflammation.
The who article which should be considered the reliable source, deosnt mention interferon beta 1a
There is definitely a lot of confusion over the WHO decision which could lead to a volatile day tomorrow unless clarified (possibly with an RNS). The article posted by T6.1 states that "The Solidarity trial is also continuing its explorations of two other treatment strategies: one involving remdesivir, an antiviral that has been shown to speed recovery in patients hospitalized with Covid-19, and a second that combines lopinavir/ritonavir with interferon beta-1a, which decreases inflammation" but the official statement from WHO does not say that. It says that the trials of hydroxychloroquine and lopinavir/ritonavir have been terminated full stop. The article posted yesterday, I think by zumzum, stated that trials of lopinavir/ritonavir have been terminated "with or without Interferon beta 1a" so we are left not knowing whether Traumakine is still part of the trial or not. All this strikes me as being highly price sensitive so I would expect an RNS in the morning.
Hi T6.1, the powers that be don't let new posters do links for a while. Try adding a few spaces so that it no longer looks like a link - then someone else can re-post it.
https://www.nytimes.com/2020/07/04/world/coronavirus-updates.html
The W.H.O. suspends two drug studies, including one on hydroxychloroquine, over possible safety issues.
The World Health Organization on Saturday formally suspended its evaluation of two high-profile drug candidates in clinical trials designed to identify treatments effective against the coronavirus.
The W.H.O. formally adopted the recommendations of a steering committee and dropped the antimalarial drug hydroxychloroquine from its Solidarity trial, as well as the drug combination lopinavir/ritonavir, first developed as an antiviral against H.I.V., the virus that causes AIDS.
Hydroxychloroquine was promoted by the Trump administration as a preventive and treatment for Covid-19, the illness caused by the coronavirus. But neither hydroxychloroquine nor lopinavir/ritonavir has shown benefits in hospitalized Covid-19 patients. In clinical trials, both drugs have failed to reduce deaths among those with severe symptoms.
And though neither drug appeared to increase the risk of death, the W.H.O. report cited possible safety issues associated with both treatments.
A similar clinical trial of hydroxychloroquine, led by the National Institutes of Health, was halted in June, based on recent evidence of the drug’s lackluster performance. Just days prior, the Swiss drugmaker Novartis had discontinued its own hydroxychloroquine clinical trial after it was unable to enroll the 440 participants it needed.
The F.D.A. has also revoked emergency use authorization of hydroxychloroquine to treat hospitalized Covid-19 patients, and now cautions against using the drug, which has been linked to reports of serious heart rhythm problems, blood and lymph system disorders and other side effects.
The W.H.O.’s decision applies only to its studies involving patients hospitalized with Covid-19, leaving open the possibility for further evaluation of hydroxychloroquine and lopinavir/ritonavir in infected patients who have not yet been admitted to the hospital, or as a treatment to prevent those exposed to the coronavirus from getting sick. In the United States, clinical trials studying both drugs continue.
The Solidarity trial is also continuing its explorations of two other treatment strategies: one involving remdesivir, an antiviral that has been shown to speed recovery in patients hospitalized with Covid-19, and a second that combines lopinavir/ritonavir with interferon beta-1a, which decreases inflammation.
Can I suggest and IMO. Marku would rather Traumakine to be a stand alone Treatment. Did "WHO" Ask Faron to partisepate In the REMAP etc Trials. Did "WHO" suggest that Traumakine be Concocted with the other Two dropped Compounds. Did Marku being the gentleman he Is Not like to refuse the "WHO" seeing the urgency In a treatment for Covid. Knowing that with All his experience that Traumakine IS a stand alone Treatment. Again AIMO.
As far as I was aware - Faron just donated 2000 doses of Interferon Beta for use in Solidarity .
Looking at the Clinicaltrial.gov lists , every reference to IFN Beta 1a in the Solidarity or Discovery trial is being administered subcutaneously .
https://clinicaltrials.gov/ct2/show/NCT04315948?term=interferon+covid&recrs=a&draw=3&rank=11
That is why I've always thought that REMAP was the trial we would be most interested in .
Being involved with WHO is something worth shouting about - but we need to look at how the interferon was used , and note it was only a bolt on to another drugs arm .
If it was all administered subcutaneously then Faron have already published papers outlining how ineffective that delivery system is .
I believe they published that to prepare the ground for when the injected form proved less than effective .
The Lopinavir arm wasn't their domain - they just supplied the raw materials .
The WHO statement doesn't even mention Interferon .
https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19
All of following is speculative and is mainly basing information we do have so far from official news.
1. Yes, we have been pulled off WHO Solidarity trial. Because of the termination lopinavir/ritonavir combination trial arm with or without interferon beta. Such issue started to emerge right after Recovery trial lopinavir/ritonavir failure; WHO is using reference to French Discovery trial, a part of WHO Solidarity. Three trials, we have been participating in one of them.
2. We will hear about signals in the clinical laboratory findings (reference to the Discovery trial) soon.
3. It is mentioned that use of lopinarir/ritonavir will be stopped in the mentioned Covid-19 trials.
4. We are pulled off because being in the Solidarity trial only with lopinavir/ritonavir, please correct me if I am mistaking here.
5. It seems from some tweets that WHO was familiar to the situation alreay in the mid-June. We even do not know, when they started to stop those Solidarity trial arms.
6. REMAP-CAP continues with Traumakine and HIBISCUS will be started. Actually being pulled off from Solidarity does not mean that use of interferons is the issue at all (until clearly indicated). By my opinion, there is no judgement on the interferons so far at all.
7. Most likely we are losing up to 2000 doses of Traumakine (If I am correct) we supplied to WHO.
8. I do not fully understand, why we joined lopinavir/ritonavir arm in the Solidarity trial. Any hidden agenda?
9. If Faron is best in the class ("Faron is all about science. We understand biology"), they should have predicted such failure of lopinavir/ritonavir.
10. No Faron's RNS during this week and during Thyrsday/Friday selloff is sign and IMO confirming that Faron is taking Solidarity results without a chaotic stress. Pulled off - yes, but not related to the interferons.
11. Indeed, there might be also contradictionary news coming in the respect of using interferons, if not administered right or in the right moment. We have patented IV use and understanding how it must be done. Will see, do this is really patent-deserving knowledge.
12. Depending of RNS (or missing of them) on Monday morning, we may meet high volatility. IMO we have not lost anything; WHO has many things to explain (there are quite silly comments in twitter against WHO and Solidarity now). I personally prefer an explanatory RNS from the management, not in the defensive language.
13. By now, and with the information we got yesterday, everything seems still quite promising. Interferons have been widely introduced and discussed. Many existing cures are not working and this was expectable. We have patented IV IFN product Traumakine which may save ARDS patient lives. We do have IFN beta 1a production knowledge, which is also an important asset. I hope we are in the safe side. Hard shake on Monday? Might be, who knows.